Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration

Background: nAMD causes vision loss in older adults. Anti-VEGF therapy improves outcomes, but long-term real-world data are limited. Objective: To assess 11-month outcomes of anti-VEGF therapy in nAMD patients. Methods: 110 patients at ESIC Medical College received intravitreal anti-VEGF on a PRN regimen. BCVA and CMT were tracked over 11 months. Results: Over 11 months, BCVA improved from 0.8 to 0.5 logMAR and CMT reduced from 420 µm to 300 µm. Vision improved in 65% of patients, with no major adverse events reported. Conclusion: Anti-VEGF therapy is effective and safe for managing nAMD with a manageable injection burden. Keywords: nAMD, anti-VEGF, BCVA, CMT